Complete, Fast, Advanced Non-Invasive Wound Care, Pain Relief & Quality Of Life Improvement
OPTIMIZE BLOOD CIRCULATION FOR SIGNIFICANT OUTCOMES!
Clinical studies with D'OXYVA® (deoxyhemoglobin vasodilator) have shown extraordinary results for the role of transdermal non-invasive wound care using cGMP-compliant ultra-purified FDA-cleared molecules, such as CO2, especially when all other approaches failed.
In an ongoing multi-year, multi-country, multi-center, randomized clinical trial on patients with diabetic foot ulcers, D'OXYVA has demonstrated speeding up diabetic wound healing and ultimately wound closure to an average of 5 weeks**.
In addition, D'OXYVA eliminated pain and improved quality of life such as sleep, appetite and mood in just a week in 100% of subjects. No adverse events of any kind were reported during, and years after the studies.
Read our clinical evidence
Patients and physicians report quicker, more comfortable diabetic wound treatment, wound closure, and overall recovery from trauma, and so-called non-healing chronic wounds related to diabetes and cardiovascular complications. Reports of significantly lower instances of pain and infection are nearly universal.
Pain-Free, Non-Invasive, Non-Electrical, Takes 5 Minutes
Affordable, Convenient, Major Clinical Outcomes in 2-6 Weeks**
Patient & Doctor-Friendly; Use at Home, in Practice, or On the Go
Non-Toxic, Non-Opioid, No Adverse Side Effects, No Overdose
Handheld, Portable, Needs No Special Storage
Effective Stand-Alone & Adjunct Solution, No Adverse Interference with Other Modalities
The following images illustrate the typical example of D'OXYVA's efficacy as a stand-alone non-invasive wound care solution for closing chronic vascular disease-related wounds. All other advanced and traditional modalities have failed after a year of expert intervention at a leading military hospital. A 5-minute (16g CO2) D'OXYVA was applied twice a day on a thumb and on the wound for a total of 4 weeks and healing continued long after.
D'OXYVA (deoxyhemoglobin vasodilator) is indicated for significant enhancements in the regulation of the autonomic nervous system (ANS), microvascular function, skin perfusion pressure, and cellular oxygen, which are being recognized in a rapidly growing number of published randomized clinical trials. D'OXYVA's advanced non-invasive wound care results have been leading to a variety of significant clinical outcomes in nearly all patients. No contraindications have been identified or recorded as of yet.
Microcirculation dysfunction is regarded by a growing number of published research papers as the underlying cause of the most widespread health complications for both the young and elderly. Among other things, restrictions in these processes impede the flow of antibodies, white blood cells and platelets, and rob the skin and body of oxygen.
D'OXYVA (deoxyhemoglobin vasodilator) is a promising upcoming microcirculation therapy. It is a relatively affordable low risk, non-invasive, natural and benign, both adjunct and standalone solution for the forward-looking health facility and patient wanting to significantly reduce cost of treatment and readmission rates, while improving patient compliance.
It is a portable device that you hold in the palm of your hand and each application takes only 5 minutes. The supersaturated medical gas vapor produced by the D'OXYVA device is almost imperceptible when gently sprayed onto the surface of the skin or near a wound.
Health professionals recommend taking D'OXYVA for wound healing twice a day with a 16g CO2 EasyTwist cartridge for 5 days per week for the first 2 weeks to evaluate progress and change regimen as necessary.
The average maintenance after complete wound closure may be as low as a single 16g CO2 D'OXYVA EasyTwist cartridge every 2 or 3 days per week. Taking D'OXYVA should be individualized according to patient characteristics such as goals of the therapy and response, and based on proper and frequent diagnosis.
Blood flow (perfusion index), oxygen (SpO2 and TcPO2), blood pressure, blood glucose, heart rate variability (sympathetic and parasympathetic nerve activity), blood pH, and other vitals are recommended to be analyzed within 2 to 4 weeks after starting D'OXYVA, and use adjusted according to results.
Stopping D'OXYVA after only 4 weeks is not recommended and it may not provide the expected long-term benefits even if major benefits and clinical outcomes were realized.
Click here or image below and see example test result
D'OXYVA DELIVERS CONSISTENT RESULTS MEASURABLE IN SECONDS - Take our guarantee challenge and you may earn free products
Essentially, Medical Carbon Dioxide is a FDA-cleared non-toxic pharmaceutical molecule (Medical Gas Safety Act 2012) and delivering it via transdermal means has demonstrated an alternative route to inhalation.
The transdermal route with Circularity's platform patented and patent-pending advanced transdermal non-invasive wound care solution is a Non-Significant Risk (NSR) Class I medical device available for medical use by prescription under the FDA's Investigational Device Exemption.
D'OXYVA inherently carries much lower risks but much greater benefits and cost savings at the same time. Physicians in the United States are allowed to prescribe and conduct research for any kind of medical purpose.
Center of Excellence (COE) Program for Health Professionals
To introduce D'OXYVA advanced non-invasive diabetic wound treatment to your patients and test it effectively, chat now or call us or contact your local Circularity-Certified Representative, ask about our Centers of Excellence program, and for the following items:
- Clinical Trial Publications, White Papers, Wound Care Brochures
- Advanced Imaging and Diagnostics Systems
- Patient Brochures, Waiting Room Posters, Banners, DVDs, and More
- Clinical Trial Protocols, Investigator's Brochures, Informed Consents
MEASURE / FEEL / SEE RESULTS IN 3 WEEKS.**
*Six years of excellent user feedback and over two dozen clinical studies demonstrated outsized results at clinics and at home with zero adverse events. For example, D'OXYVA® (deoxyhemoglobin vasodilator) has been recording significant results also as a varicose vein treatment while delivering major clinical outcomes for well over 90% of users. Average results rounded for display, based on number of enrolled subjects in each clinical study with D'OXYVA and user feedback.
Back to Top ^
Read D'OXYVA Clinical Evidence
**Individual results may vary. Ask your doctor before taking D'OXYVA. For prescription for medical use.
Read D'OXYVA Regulatory Statements
***We will refund your entire D'OXYVA purchase price if you do not achieve any improvements (proof of purchase required, improvements of blood flow (perfusion index) measured from absolute baseline without taking D'OXYVA).
Read Circularity's Return Policy